Management of Lung Cancer: Localized, Locally Advanced, and Metastatic Disease
Localized Disease (Stage I-II)
Surgery with anatomical resection (lobectomy preferred) is the definitive treatment for stage I-II NSCLC, followed by adjuvant cisplatin-based chemotherapy for stage II and III disease. 1
Surgical Approach
- Lobectomy remains the standard for tumors ≥2 cm with solid appearance on CT 1
- Anatomical segmentectomy is acceptable only for pure ground-glass opacities or minimally invasive adenocarcinomas 1
- VATS should be the preferred approach for stage I tumors when surgeon expertise allows 1
- Wedge resection is inferior and should be avoided 1
Adjuvant Therapy
- Adjuvant cisplatin-based doublet chemotherapy is mandatory for resected stage II-III NSCLC 1
- Consider for stage IB tumors >4 cm 1
- Cisplatin-vinorelbine is the most extensively studied regimen, with cumulative cisplatin dose up to 300 mg/m² over 3-4 cycles 1
- Do not use molecular markers (ERCC1, mutations) to guide adjuvant therapy selection 1
- Targeted agents have no role in the adjuvant setting 1
Non-Surgical Candidates
- Stereotactic ablative radiotherapy (SABR) is the treatment of choice for medically inoperable stage I disease 1
- Dose: biologically equivalent tumor dose ≥100 Gy to encompassing isodose 1
- For tumors >5 cm or moderately central location, use conventional/accelerated radiotherapy schedules 1
- Postoperative radiotherapy is NOT recommended for completely resected early-stage disease 1
Locally Advanced Disease (Stage III)
Concurrent chemoradiotherapy is the standard treatment for unresectable stage III NSCLC, followed by consolidation durvalumab immunotherapy for up to 12 months. 2
Initial Staging Requirements
- Contrast-enhanced CT chest/upper abdomen plus PET-CT within 4 weeks before treatment 2
- Brain MRI is mandatory for all stage III patients planned for curative treatment (contrast-enhanced brain CT if MRI unavailable) 2
- Multidisciplinary assessment required for resectability determination 2
- Pathological confirmation needed for solitary PET-positive distant lesions 2
Chemoradiotherapy Protocol
For Fit Patients (PS 0-1):
- Concurrent chemoradiotherapy is superior to sequential and is the treatment of choice 2, 3
- Platinum-based doublet: cisplatin-etoposide or cisplatin-vinorelbine (cisplatin-pemetrexed for non-squamous) 2
- Carboplatin-paclitaxel shows inferior outcomes but may be used for comorbidity issues 3
- 2-4 cycles of concurrent chemotherapy during radiotherapy 2
- Radiation dose: 60-66 Gy in 30-33 fractions, maximum treatment time ≤7 weeks 2
For Elderly/Unfit Patients:
- Sequential chemotherapy followed by radiotherapy is acceptable 2, 3
- Carboplatin monotherapy may be considered in patients >70 years 2
- When using sequential approach, deliver radiotherapy in short overall treatment time 2
Critical Post-Chemoradiotherapy Management
Consolidation durvalumab (10 mg/kg every 2 weeks for up to 12 months) started 1-42 days after completing chemoradiotherapy demonstrates survival benefit and is strongly recommended. 2 This represents the most significant advance in stage III management.
What NOT to Do
- No prophylactic cranial irradiation in stage III NSCLC 2
- No induction or consolidation chemotherapy beyond concurrent cycles 2
- No consolidation with docetaxel or EGFR-TKI 3
Resectable Stage III (Selected N2 Disease)
- Both definitive chemoradiotherapy and induction therapy followed by surgery are options 3
- Surgery preferred only when complete resection by lobectomy is expected 3
- Complex resections should be performed only in experienced centers 3
- Postoperative radiotherapy may be considered for N2 patients after resection, though unproven; indicated after incomplete resection 3
Metastatic Disease (Stage IV)
Treatment strategy must be determined by molecular testing results, PD-L1 expression, histology, and performance status—systemic therapy should be offered to all PS 0-2 patients. 4
Essential Workup
- Contrast-enhanced CT chest/upper abdomen 4
- Brain imaging (MRI preferred) should be considered for all metastatic patients and is required with neurological symptoms 4
- Bone imaging if clinically suspected 4
- Molecular testing is mandatory before treatment initiation (EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS G12C) 5, 6
- PD-L1 testing required 4
First-Line Treatment Algorithm
For EGFR/ALK-Negative Disease:
PD-L1 ≥50% (PS 0-1):
- Pembrolizumab monotherapy is the preferred option 4
- Chemotherapy only if immunotherapy contraindicated 4
PD-L1 <50% or Any PD-L1 Level:
Non-Squamous:
- Pembrolizumab + pemetrexed + platinum (benefit across all PD-L1 levels, though diminished in PD-L1-negative) 4
- Alternative: Atezolizumab + bevacizumab + carboplatin + paclitaxel 4
Squamous:
- Pembrolizumab + carboplatin + (paclitaxel or nab-paclitaxel) 4
For Actionable Mutations:
- Targeted therapy is first-line for patients with druggable oncogenic drivers 5, 6
- Specific agents depend on mutation identified
Response Monitoring
- Reassess after 6-9 weeks using same imaging modality 4
- Use RECIST v1.1 criteria 4
- For immunotherapy, consider irRECIST/iRECIST/imRECIST for overall assessment 4
- PET not routinely recommended for follow-up (high sensitivity, low specificity) 4
Follow-Up After Curative-Intent Treatment
Surveillance every 6 months for 2 years with contrast-enhanced chest CT at minimum at 12 and 24 months, then annually thereafter. 2
- Each visit: history, physical examination, chest CT 2, 3
- More frequent visits may be needed in first year for radiation toxicity management 2
- For patients suitable for salvage treatment: 6-monthly scans for 3 years 2
- Monitor for treatment complications, treatable relapse, and second primary lung cancers 2, 3
Common Pitfall
The 2013 guidelines 3 recommend follow-up every 3-6 months, but the more recent 2020 Pan-Asian adapted guideline 2 specifies every 6 months with mandatory CT at 12 and 24 months—follow the more structured 2020 protocol for consistency.